| Literature DB >> 25161649 |
Fabian Cieplik1, Laura Tabenski1, Wolfgang Buchalla1, Tim Maisch2.
Abstract
With increasing numbers of antibiotic-resistant pathogens all over the world there is a pressing need for strategies that are capable of inactivating biofilm-state pathogens with less potential of developing resistances in pathogens. Antimicrobial strategies of that kind are especially needed in dentistry in order to avoid the usage of antibiotics for treatment of periodontal, endodontic or mucosal topical infections caused by bacterial or yeast biofilms. One possible option could be the antimicrobial photodynamic therapy (aPDT), whereby the lethal effect of aPDT is based on the principle that visible light activates a photosensitizer (PS), leading to the formation of reactive oxygen species, e.g., singlet oxygen, which induce phototoxicity immediately during illumination. Many compounds have been described as potential PS for aPDT against bacterial and yeast biofilms so far, but conflicting results have been reported. Therefore, the aim of the present review is to outline the actual state of the art regarding the potential of aPDT for inactivation of biofilms formed in vitro with a main focus on those formed by oral key pathogens and structured regarding the distinct types of PS.Entities:
Keywords: aPDT; antibiotic resistance; antimicrobial; biofilm; oral; photodynamic
Year: 2014 PMID: 25161649 PMCID: PMC4130309 DOI: 10.3389/fmicb.2014.00405
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Type I and type II processes of aPDT. Visible light of an appropriate wavelength is absorbed by the PS molecule by what the PS changes from its initial ground state S0 to an energetically excited state S1. Thereupon the PS is able to transition within the molecule from its singlet to its triplet state T1 (inter-system crossing). This T1 state is long-living compared to S1 so that charge (type I) or energy (type II) can be transferred to surrounding molecules such as oxygen with emergence of oxygen radicals (type I) or singlet oxygen (type II).
Figure 2Phenothiazinium derivatives. Chemical structures of phenothiazinium derivatives: (A) Methylene Blue. (B) Toluidine Blue. (C) Safranine O.
General characteristics of studies examining phenothiazinium derivatives.
| Fontana et al., | MB | 25 μg/ml | 5 min | Diode laser (1 W; 665 nm) | 5 min | 30 J/cm2 | 8% | No | |
| 50 μg/ml | 32% | ||||||||
| Rossoni et al., | MB | 300 μ M | 5 min | GaAlAs laser (35 mW; 660 nm) | 285 s | 26.3 J/cm2 | Serotype A: ≥2 log10 | No | |
| Serotype B: ≤1 log10 | No | ||||||||
| Zanin et al., | TBO | 100 mg/l | 5 min | HeNe gas laser (32 mW; 632.8 nm) or LED (32 mW; 620–660 nm, maximum: 638.8 nm) | 5, 10, or 15 min | 49, 147, or 294 J/cm2 | 2–5 log10 | Yes | |
| Zanin et al., | TBO | 100 mg/l | 5 min | LED (32 mW, 620–660 nm, maximum: 638.8 nm) | 7 min | 85.7 J/cm2 | No | ||
| Yes | |||||||||
| Teixeira et al., | TBO | 100 mg/l | 5 min | LED (40 mW, 620–660 nm, maximum: 638.8 nm) | 15 min | 55 J/cm2 | ≥5 log10 | Yes | |
| < 1 log10 | No | ||||||||
| Kishen et al., | MB | 100 μ M | 15 min | Noncoherent light source with 30 nm bandpass filters (300–600 mW; MB: 660 ± 15 nm; RB: 540 ± 15 nm) | n/s | 10–40 J/cm2 | ≥5 log10 | Yes | |
| RB | 100 μ M | 15 min | n/s | 10–40 J/cm2 | ≈ 5 log10 | Yes | |||
| Meire et al., | TBO (PAD™) | 12.7 mg/l | 2 min | Soft diode laser (100 mW; 635 nm) | 2.5 min | n/s | <1 log10 | No | |
| MB (HELBO®) | 10 mg/ml | 3 min | Soft laser (75 mW; 660 nm) | 2 min | n/s | ≈ 2 log10 | No | ||
| NaOCl | 2.5% | 1, 5, 10, or 30 min | ≥6 log10 | Yes | |||||
| Er:YAG laser (2940 nm; 15 Hz) | 40 s | 50 mJ | <1 log10 | No | |||||
| 100 mJ | ≥4 log10 | Yes | |||||||
| Nd:YAG laser (1064 nm; 15 Hz) | 40 s | 2 W | <1 log10 | No | |||||
| Zand et al., | TBO | 25 μg/ml | 5 min | Diode laser (100 mW; 625 nm) | 2 × 2.5 min (intermitted by 2.5 min break) | 214.28 J/cm2 30 J | Total elimination (below detection limit of CFU-assay) | Yes | |
| Fimple et al., | MB | 25 μg/ml | 10 min | Diode laser (1 W; 665 nm) coupled to an optical fiber | 2 × 2.5 min (intermitted by 2.5 min break) | 30 J/cm2 | 80% | No | |
| Voos et al., | Safranine O | 10 μ M | 15 min | Diode laser (0.5 W; 532 nm) | 40 s | 20 J/cm2 | 24 h: 2 log10 | No | |
| 72 h: - | No | ||||||||
| 100 s | 50 J/cm2 | 24 h: 3 log10 | Yes | ||||||
| 72 h: - | No |
According to the ASM it is necessary to prove a reduction of 3 log10 steps of CFU for being able to use the terms “antimicrobial” or “antibacterial.”
Figure 3Porphyrin and chlorin derivatives. Chemical structures of porphyrin and chlorin derivatives: (A) TMPyP. (B) XF-73. (C) Photodithazine®.
General characteristics of studies examining porphyrin and chlorin derivatives.
| Di Poto et al., | TMPyP | 10 μ M | 15 min | Tungsten lamp (166 mW/cm2; 400–800 nm) | n/s | 150–200 J/cm2 | 1 to 2 log10 | No | |
| Collins et al., | TMPyP | 225 μ M | 0 min | Mercury vapor lamp (100 W; ≥ 400 nm) | 10 min | 220–240 J/cm2 | 4 log10 | Yes | |
| Cieplik et al., | TMPyP | 100 μ M | 60 min | LED light-curing unit (1360 mW/cm2; at sample level: 600 mW/cm2; 460 ± 20 nm) | 120 s | Total absorbed energy: 80 J | No effect | No | |
| SAPYR | 100 μ M | 60 min | 120 s | total absorbed energy: 12.5 J | ≥5 log10 | Yes | |||
| ≥5 log10 | Yes | ||||||||
| ≥2 log10 | Yes | ||||||||
| ≥4 log10 | Yes | ||||||||
| Gonzales et al., | TMPyP | 0.1–50 μ M | 4 h | Incoherent light source (at sample level: 13.4 mW/cm2; 418 ± 20 nm) | 60 min | 48.2 J/cm2 | 50 μ M: ≥5 log10 | Yes | |
| XF-73 | 0.1–10 μ M | 4 h | 60 min | 48.2 J/cm2 | 1 μ M: ≥5 log10 | Yes | |||
| Quishida et al., | Photodithazine® | 100–250 mg/l | 20 min | LED (71 mW/cm2; 660 nm) | 9 min | 37.5 J/cm2 | No | ||
| No | |||||||||
| Dovigo et al., | Clinical isolates of | Photodithazine® | 125 mg/l | 20 min | LED (25 mW/cm2; 660 ± 20 nm) | n/s | 37.5 J/cm2 | ≈ 1 log10 | No |
According to the ASM it is necessary to prove a reduction of 3 log10 steps of CFU for being able to use the terms “antimicrobial” or “antibacterial.”
Figure 4Fluorescein derivatives. Chemical structures of fluorescein derivatives: (A) Eosin Y. (B) Erythrosine. (C) Rose Bengal. (D) Chitosan-conjugated Rose Bengal.
General characteristics of studies examining fluorescein derivatives.
| Wood et al., | ERY | 22 μ M | 15 min | Tungsten filament lamp (ERY: 22.7 mW/cm2; 500–550 nm; MB, Photofrin: 22.5 mW/cm2; 600–650 nm) | 15 min | n/s | 48 h: 2.2 log10 | No | |
| 288 h: 3 log10 | Yes | ||||||||
| MB | 22 μ M | 15 min | 15 min | n/s | 48 h: 1.5 log10 | No | |||
| 288 h: 2.6 log10 | No | ||||||||
| Photofrin | 22 μ M | 15 min | 15 min | n/s | 48 h: 0.5 log10 | No | |||
| 288 h: 1.1 log10 | No | ||||||||
| Metcalf et al., | ERY | 22 μ M | 15 min | Tungsten filament lamp (ERY: 22.7 mW/cm2; 500–550 nm) | 5 min | 6.75 J/cm2 | 2 log10 | No | |
| 5 × 1 min (5 min breaks) | 6.75 J/cm2 | 3 log10 | Yes | ||||||
| 10 × 30 s (2 min breaks) | 6.75 J/cm2 | 3.7 log10 | Yes | ||||||
| Pereira et al., | ERY | 5 μ M | 5 min | LED (200 mW; 455±20 nm) | 180 s | 95 J/cm2; 36 J | No | ||
| No | |||||||||
| RB | 5 μ M | 5 min | 180 s | 95 J/cm2; 36 J | No | ||||
| No | |||||||||
| Freire et al., | RB | 200 μ M | 5 min | LED (90 mW; 532±10 nm) | 180 s | 42.63 J/cm2; 16.2 J | 22% | No | |
| Eosin Y | 200 μ M | 5 min | 180 s | 42.63 J/cm2; 16.2 J | 45% | No | |||
| Kishen et al., | RB | 100 μ M | 15 min | Noncoherent light source with 30 nm bandpass filters (300–600 mW; RB: 540±15 nm; MB: 660±15 nm) | n/s | 10–40 J/cm2 | ≈ 5 log10 | Yes | |
| MB | 100 μ M | 15 min | n/s | 10–40 J/cm2 | ≥ 5 log10 | Yes | |||
| Shrestha and Kishen, | CSRB | 0.3 mg/ml | 15 min | Fibers (n/s; CSRB, RB: 540 nm; MB: 660 nm) | n/s | 40 J/cm2 | Yes | ||
| Yes | |||||||||
| RB | 10 μ M | 15 min | n/s | 40 J/cm2 | Yes | ||||
| Yes | |||||||||
| MB | 10 μ M | 15 min | n/s | 40 J/cm2 | Yes | ||||
| Yes |
According to the ASM it is necessary to prove a reduction of 3 log10 steps of CFU for being able to use the terms “antimicrobial” or “antibacterial.”
Figure 5Curcumin, perinaphthenone and fullerene derivatives. Chemical structures of curcumin, perinaphthenone and fullerene derivatives: (A) Curcumin. (B) PNS. (C) SAPYR. (D) Fullerene C60.
General characteristics of studies examining curcumin and perinaphthenone derivative.
| Araújo et al., | Curcumin | 0.75 to 5 g/l | 5 min | LED (19 mW/cm2; central wavelength: 450 nm) | 5 min | 5.7 J/cm2 | ≥3 log10 (above 3 g/l) | Yes | |
| 69% (at 5 g/l) | No | ||||||||
| Cieplik et al., | SAPYR | 100 μ M | 60 min | LED light-curing unit (1360 mW/cm2; at sample level: 600 mW/cm2; 460 ± 20 nm) | 120 s | Total absorbed energy: 12.5 J | ≥5 log10 | Yes | |
| ≥5 log10 | Yes | ||||||||
| ≥2 log10 | Yes | ||||||||
| ≥4 log10 | Yes | ||||||||
| TMPyP | 100 μ M | 60 min | 120 s | Total absorbed energy: 80 J | No effect | No |
According to the ASM it is necessary to prove a reduction of 3 log10 steps of CFU for being able to use the terms “antimicrobial” or “antibacterial.”